Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

The Role of the Alternative Lengthening of Telomeres Pathway and p53 Status in Breast Cancer Chemoresistance.

EF 2016-17

Résumé
Telomeres are protective stretches of DNA at the ends of chromosomes that shorten each time a cell divides. This imposes a limit on how much normal cells can divide. A hallmark of cancer cells is the ability to divide endlessly, which necessitates a means to lengthen their telomeres. Telomerase is an enzyme that can accomplish this and is present in most cancers while being absent in most normal cells, making it a promising target in cancer therapy. However, ~15% of cancers do not rely on telomerase and instead use a separate Alternative Lengthening of Telomeres (ALT) mechanism that is based on DNA repair. ALT poses a challenge because it provides a way for cancer cells to escape treatment and become resistant. As of late, it remains unclear what causes ALT to be activated. Our lab has shown that damage to telomeres in a ALT negative breast cancer cell line can cause emergence of ALT features. Studies have also shown that some chemotherapeutic drugs widely used in the treatment of breast cancer such as doxorubicin can cause damage to telomeres. Based on these evidences, we propose that treatment with certain chemotherapeutic drugs can favour ALT activation. Enhancing our understanding of ALT can allow for the use and development of drugs that do not favour ALT activation. In addition, we are interested in a possible role of p53, a protein nicknamed the ""guardian of the genome"", in repressing ALT. Previous studies have shown that mutations in p53 are highly associated with ALT, and preliminary data from our lab has shown that removal of p53 in a breast cancer cell line causes an increase in ALT features. Understanding the regulators and markers of ALT can allow for better decisions to be made in respect to cancer therapy, and may identify new avenues for the same.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367396
Name
Wang Jeffery
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of the Alternative Lengthening of Telomeres Pathway and p53 Status in Breast Cancer Chemoresistance.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alternative Lengthening Of Telomeres; Breast Cancer; Cancer; Chemoresistance; Chemotherapeutics; P53; Telomeres
Abstract
Telomeres are protective stretches of DNA at the ends of chromosomes that shorten each time a cell divides. This imposes a limit on how much normal cells can divide. A hallmark of cancer cells is the ability to divide endlessly, which necessitates a means to lengthen their telomeres. Telomerase is an enzyme that can accomplish this and is present in most cancers while being absent in most normal cells, making it a promising target in cancer therapy. However, ~15% of cancers do not rely on telomerase and instead use a separate Alternative Lengthening of Telomeres (ALT) mechanism that is based on DNA repair. ALT poses a challenge because it provides a way for cancer cells to escape treatment and become resistant. As of late, it remains unclear what causes ALT to be activated. Our lab has shown that damage to telomeres in a ALT negative breast cancer cell line can cause emergence of ALT features. Studies have also shown that some chemotherapeutic drugs widely used in the treatment of breast cancer such as doxorubicin can cause damage to telomeres. Based on these evidences, we propose that treatment with certain chemotherapeutic drugs can favour ALT activation. Enhancing our understanding of ALT can allow for the use and development of drugs that do not favour ALT activation. In addition, we are interested in a possible role of p53, a protein nicknamed the ""guardian of the genome"", in repressing ALT. Previous studies have shown that mutations in p53 are highly associated with ALT, and preliminary data from our lab has shown that removal of p53 in a breast cancer cell line causes an increase in ALT features. Understanding the regulators and markers of ALT can allow for better decisions to be made in respect to cancer therapy, and may identify new avenues for the same.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Jeffery
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~